

Joint Meeting of the National Center for Advancing Translational Sciences Advisory Council (21st) and Cures Acceleration Network Review Board (27th)

Building 35A, Conference Rooms 620/630, NIH Campus, Bethesda, Maryland

Open Session of the meeting will be webcast. To view, please go to: https://videocast.nih.gov/summary.asp?live=32005.

Agenda

Thursday, May 16, 2019	Thursd	lav.	Mav	16.	2019
------------------------	--------	------	-----	-----	------

	Wildy 10, 2013
8:30 am	Call to Order, Open Session
	Christopher P. Austin, M.D., Director, NCATS; Chairperson – NCATS Advisory Council
	 G. Lynn Marks, M.D., Senior R&D Advisor, Biomedical Advanced Research and Development Authority (BARDA), ASPR/HHS - Chairperson - CAN Review Board
	Confirmation of Dates for Future NCATS Advisory Council/CAN Review Board Meetings
	Approval of Minutes from January 2019 Joint Meeting
	 Anna L. Ramsey-Ewing, Ph.D., Director, Office of Grants Management and Scientific Review, NCATS – Executive Secretary, NCATS Advisory Council and CAN Review Board
8:45 am	Introduction of New Staff
	NCATS Staff
	Director's Report
	Christopher P. Austin, M.D., Director, NCATS
	Discussion
9:45 am	BREAK
10:00 am	CTSA Program Update
	Michael G. Kurilla, M.D., Ph.D., Director, Division of Clinical Innovation, NCATS
	Discussion
10:45 am	Division of Pre-Clinical Innovation Update
	Anton Simeonov, Ph.D., Scientific Director, Division of Pre-Clinical Innovation, NCATS
	Christine M. Colvis, Ph.D., Director, Drug Development Partnership Programs, NCATS
	Discussion
11:30 am	Cures Acceleration Network Review Board Update
	 G. Lynn Marks, M.D., Senior R & D Advisor, Biomedical Advanced Research and Development Authority (BARDA), ASPR/HHS - Chairperson - CAN Review Board
	Discussion

12:00 pm	LUNCH			
1:00 pm	Clearance of Concepts: Presentations and Discussions Order of Magnitude Increases in the Efficiency of Adeno-Associated Virus (AAV) Vector Production for Human Gene Therapy P.J. Brooks, Ph.D., Program Director, Office of Rare Diseases Research, NCATS Ethical, Legal and Societal Implications in Translational Research Elaine Collier, M.D., Senior Advisor to the Director, NCATS Introduction of SBIR/STTR Concepts Lili Portilla, M.P.A., Director, Office of Strategic Alliances, NCATS Non-viral Delivery Technologies for Somatic Genome Editing Therapeutics P.J. Brooks, Ph.D., Program Director, Office of Rare Diseases Research, NCATS Alternatives to Commercially Available Membrane Inserts and Manufacturing Techniques Sam Michael, Director, Automation and Compound Management, NCATS Multi-disciplinary Approaches to Shortening the Diagnostic Odyssey for Rare Diseases Anne R. Pariser, M.D., Director, Office of Rare Diseases Research, NCATS			
2:30 pm	Adjourn, Open Session ➤ Christopher P. Austin, M.D., Director, NCATS; Chairperson – NCATS Advisory Council ➤ G. Lynn Marks, M.D., Senior R&D Advisor, Biomedical Advanced Research and Development Authority (BARDA), ASPR/HHS - Chairperson - CAN Review Board			
	BREAK			
3:00 pm	Call to Order, Closed Session			
4:30 pm	Adjourn, Closed Session			

Future Advisory Council and CAN Review Board Joint Meetings							
<u>2019</u>	<u>2020</u>	<u>2021</u>					
	January 16	January 14					
	May 14	May 20					
September 19	September 17	September 23					
Future CAN Review Board (only) Meetings (virtual) 2019 2020 2021							
<u>2019</u> December 13	December 11	December 10					
December 13	December 11	December 10					